ArticleThe EMBO journal2021
NHP2 downregulation counteracts hTR-mediated activation of the DNA damage response at ALT telomeres.
Article in The EMBO journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- Alternative Lengthening of Telomeres: The Need forInternational journal of molecular sciences · 2025Article
- Article
- A novel lncRNA YIL163C enhances genomic stability and antifungal resistance via the DNA damage response inFrontiers in microbiology · 2025Article
- Maintenance of R-loop structures by phosphorylated hTERT preserves genome integrity.Nature cell biology · 2024Article
- Telomere-related DNA damage response pathways in cancer therapy: prospective targets.Frontiers in pharmacology · 2024Review
- Novel pathological variants of NHP2 affect N-terminal domain flexibility, protein stability, H/ACA Ribonucleoprotein (RNP) complex formation and telomerase activity.Human molecular genetics · 2023Article
- Many Functions of Telomerase Components: Certainties, Doubts, and Inconsistencies.International journal of molecular sciences · 2022Review
- Photo-induced telomeric DNA damage in human cancer cells.RSC chemical biology · 2022Article
- Detection of alternative lengthening of telomeres mechanism on tumor sections.Molecular biomedicine · 2021Article
- Arabidopsis retains vertebrate-type telomerase accessory proteins via a plant-specific assembly.Nucleic acids research · 2021Article
- NHP2 downregulation counteracts hTR-mediated activation of the DNA damage response at ALT telomeres.The EMBO journal · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
About 10% of cancer cells employ the "alternative lengthening of telomeres" (ALT) pathway instead of re-activating the hTERT subunit of human telomerase. The hTR RNA subunit is also abnormally silenced in some ALT
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.